In obese mice, the administration of a GPR120-selective agonist has shown promising effects in enhancing glucose tolerance, improving insulin sensitivity, reducing hyperinsulinemia, and alleviating hepatic steatosis, all likely due to the increased insulin secretion [85,86]. Here, INS is linked to hyperinsulinism.